Century Therapeutics presents novel iPSC-derived cell therapy preclinical data at AACR 2024

Century Therapeutics, Inc.

CD19xCD22 bispecific CAR showed cytotoxicity against CD19/CD22 tumor cells in vitro and in xenograft models.
Allo-Evasion platform: combining HLA-E and HLA-G offered best protection against NK-mediated rejection of iPSC-derived cells.
NECTIN4-targeted iPSC-derived CAR-T demonstrated tumor inhibition comparable to Enfortumab-based CAR in OVCar-3 xenografts.
CXCR4 transgene in iPSC-derived NK cells enhanced migration and anti-tumor efficacy in vivo, eliminating bone disease.
Novel inhibitory CAR targeting DSG1 designed to reduce off-tumor skin toxicity of NECTIN4 therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.